Studying how genetic testing can improve medication use in patients
Official title: The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
Run by University of Chicago · NCT01280825 · Data updated 2026-11-12
This study is trying to see if using genetic testing can help doctors choose the right medications for patients with heart diseases, inflammatory bowel diseases, and autoimmune diseases to improve their treatment outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1200 (estimated) |
| Sponsor | University of Chicago Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Status | Recruiting |
| Started | January 14, 2011 |
| Main results expected | November 14, 2027 |
| Study ends | December 14, 2027 |
| Registry record updated | March 4, 2026 |
| Trial ID | NCT01280825 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients aged 18 and older who are receiving ongoing outpatient care and are taking at least one prescription medication.
✕Probably not a fit
Patients who are not currently on any prescription medications or those with a life expectancy of less than three years may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect DNA samples from patients receiving routine care at the University of Chicago Medical Center. The samples will be analyzed for genetic variations that may indicate a higher risk of side effects or a greater likelihood of benefit from specific medications. The findings will be shared with the patients' treating physicians, and the study will track how this genetic information is utilized in clinical practice. The focus is on patients with conditions such as heart diseases, inflammatory bowel diseases, and autoimmune diseases.
Why it matters
Potential benefit: If successful, this study could lead to more personalized medication management, reducing adverse drug reactions and improving treatment outcomes.
How similar studies have gone: Other studies have shown promise in using pharmacogenomic testing to tailor medication therapies, indicating that this approach has potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Receiving ongoing, out-patient care at the University of Chicago Medical Center under the routine care of a physician participating in this trial * Life expectancy of at least 3 years * Must be 18 years or older * Must be taking at least 1 (but not more than 6) prescription medications at the time of enrollment OR be 65 years or older OR be reasonably expected to require the use of a prescription medication within the next 5 years * Patients with certain diseases, or likely to receive or be receiving certain drugs, will be targeted particularly for enrollment in order to enrich the study for patients likely to have pharmacogenetically relevant interactions, including, but not limited to: * Patients requiring specialized cardiology care * Patients with inflammatory bowel diseases * Patients with systemic autoimmune or inflammatory diseases * Patients requiring long-term oral anticoagulation * Patients with hepatitis C * Patients with non-metastatic cancer Exclusion Criteria: * Patients with acute or chronic disease which could be reasonably expected to result in the patient's death within the next 3 years. * Patients who have undergone, or are being actively considered for, liver or kidney transplantation. * Inability to understand and give informed consent to participate.
Where it's running
-
University of Chicago Medical Center
Chicago, Illinois, United States Recruiting
Study contacts
- Principal investigator: Peter H O'Donnell, MD — University of Chicago
- Study coordinator: 1200 Patients Project Study Team
- Email: cpt1200@uchicago.edu
- Phone: (773) 834-1759
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease
This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.
-
Intestinal ultrasound-guided management for inflammatory bowel disease
This study tests if adding point-of-care intestinal ultrasound at every visit changes treatment decisions for adults with Crohn’s disease or ulcerative colitis undergoing disease assessment.
-
TRIFORMIS RESILIA heart valve real-world results in tricuspid disease
A real-world, observational study to see how the Edwards TRIFORMIS RESILIA tricuspid heart valve performs in adults needing tricuspid valve replacement.
-
Resting energy use in kids with inflammatory bowel disease
This multicenter study will test the resting energy expenditure of children aged 6–17 with new IBD diagnoses to see how it relates to disease activity and treatment.
-
Multimodal Eye Data Bank to Explore Inflammation-Related Eye Diseases
This observational effort collects rich eye-imaging data from people with inflammatory and retinal conditions to see how the front and back of the eye relate and to build a standardized database that could support future AI tools.
-
Active video education by disease subtype to improve bowel prep before colonoscopy
We’re testing whether adding subtype-specific video education to standard prep improves bowel cleanliness in adults with IBD undergoing colonoscopy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.